surgical oncology

Closing the Gap: How Equitably Applying Minimally Invasive Surgery Could Transform Colon Cancer Outcomes

By MedXY 02/18/2026

A population-based study in England reveals that correcting socioeconomic and clinical inequalities in the use of minimally invasive surgery for colon cancer significantly reduces hospital stays and 1-year mortality, highlighting a critical opportunity for health policy intervention.

news Oncology Respiratory

Histologic Subtype Dictates the Survival Benefit of Guideline-Adherent Lymph Node Dissection in T1N0M0 Lung Adenocarcinoma

By MedXY 01/27/2026

A large-scale multicenter study reveals that adherence to lymph node dissection guidelines significantly improves survival in early-stage lung adenocarcinoma patients with high-grade histologic patterns, while offering no significant benefit for those with low-risk lepidic-predominant tumors.

General Surgery news Oncology

EsoTIME: Precision Survival Prediction Replaces Traditional Staging for Resected Esophageal and Gastroesophageal Junction Cancers

By MedXY 01/23/2026

The EsoTIME tool provides a validated, high-accuracy method for predicting 3-year survival in patients with resected esophageal and gastroesophageal junction cancers, utilizing population-based data to improve personalized clinical decision-making.

General Surgery news Oncology

Beyond Nodal Status: A New Risk Score Predicts Recurrence in Lymph Node-Negative Pancreatic Neuroendocrine Tumors

By MedXY 12/22/2025

A multi-center study in JAMA Surgery introduces a validated 13-point risk score to identify recurrence risk in LN-negative PanNET patients, revealing that tumor size, grade, and lymphovascular invasion are critical prognostic drivers even when nodes are clear.

news Oncology Radiology

Streamlining Sarcoma Care: Five-Day Preoperative Radiation Matches Long-Term Efficacy of 5-Week Regimens

By MedXY 12/21/2025

A Phase 2 clinical trial reveals that an ultrahypofractionated 5-day preoperative radiation regimen for high-risk soft tissue sarcoma provides durable local control and favorable late-term toxicity compared to the conventional 5-week course, potentially revolutionizing the standard of care for patient convenience.

General Surgery news Oncology

Thoracoscopic versus Open Oesophagectomy for Thoracic Oesophageal Cancer: Insights from the JCOG1409 MONET Trial

By MedXY 10/19/2025

The JCOG1409 MONET phase 3 trial establishes that thoracoscopic oesophagectomy is non-inferior to open oesophagectomy in overall survival for resectable thoracic oesophageal cancer, with comparable safety profiles and postoperative outcomes.